Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3930890 | European Urology Supplements | 2007 | 7 Pages |
Abstract
Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kurt Miller, Per-Anders Abrahamsson, Koichiro Akakura, Frans M.J. Debruyne, Christopher P. Evans, Laurence Klotz,